Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics (ALGS) has announced an inducement grant of non-qualified stock options to a newly hired employee. The grant, issued on December 10, 2024, allows for the purchase of 5,500 shares of company stock. The exercise price equals the closing price of Aligos' common stock on the grant date. The shares will vest over four years, with 25% vesting after the first year and the remainder vesting in equal monthly installments, contingent on continued employment. The grant was made under Aligos' 2024 Inducement Plan, exclusively used for equity awards to new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).
Aligos Therapeutics (ALGS) ha annunciato un’indennità di stock option non qualificate per un nuovo dipendente assunto. L'indennità, emessa il 10 dicembre 2024, consente l'acquisto di 5.500 azioni della società. Il prezzo di esercizio è pari al prezzo di chiusura delle azioni ordinarie di Aligos nella data dell'indennità. Le azioni acquisteranno valore in quattro anni, con il 25% che matura dopo il primo anno e il resto che matura in rate mensili uguali, contingentato al mantenimento dell'impiego. L'indennità è stata concessa nell'ambito del Piano di Indennità 2024 di Aligos, utilizzato esclusivamente per premi azionari per i nuovi assunti, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Aligos Therapeutics (ALGS) ha anunciado una concesión de opciones sobre acciones no calificadas para un nuevo empleado contratado. La concesión, emitida el 10 de diciembre de 2024, permite la compra de 5,500 acciones de la compañía. El precio de ejercicio equivale al precio de cierre de las acciones ordinarias de Aligos en la fecha de concesión. Las acciones se adquirirán a lo largo de cuatro años, con un 25% que se adquirirá después del primer año y el resto adquirirá en cuotas mensuales iguales, sujeto a la continuidad del empleo. La concesión se realizó bajo el Plan de Inducción 2024 de Aligos, utilizado exclusivamente para otorgar premios de acciones a nuevos contratados, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Aligos Therapeutics (ALGS)는 새로 채용된 직원에게 비자격 주식 옵션에 대한 유도 보조금을 발표했습니다. 이 보조금은 2024년 12월 10일에 발행되었으며, 회사 주식 5,500주를 구매할 수 있습니다. 행사 가격은 주식 보조금일의 Aligos 일반 주식 종가와 동일합니다. 이 주식은 4년 동안 권리가 부여됩니다, 첫 해가 지난 후 25%가 부여되고 나머지는 계속 고용 조건에 따라 매달 동일한 비율로 부여됩니다. 이 보조금은 Nasdaq 상장 규정 5635(c)(4)에 따라, 신규 채용에 대한 주식 보상을 위해 독점적으로 사용되는 Aligos의 2024 유도 계획에 따라 제공되었습니다.
Aligos Therapeutics (ALGS) a annoncé une allocation d'options d'actions non qualifiées pour un nouvel employé embauché. L'allocation, émise le 10 décembre 2024, permet l'achat de 5 500 actions de la société. Le prix d'exercice est égal au prix de clôture de l'action ordinaire d'Aligos à la date de l'allocation. Les actions s'acquitteront sur quatre ans, avec 25 % acquérant des droits après la première année et le reste acquérant des droits en versements mensuels égaux, sous réserve d'une poursuite de l'emploi. L'allocation a été faite dans le cadre du Plan d'Incitatif 2024 d'Aligos, utilisé exclusivement pour les attributions d'équité aux nouveaux employés, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Aligos Therapeutics (ALGS) hat einen Anreizzuschuss in Form von nicht qualifizierten Aktienoptionen für einen neu eingestellten Mitarbeiter angekündigt. Der Zuschuss, der am 10. Dezember 2024 ausgegeben wurde, ermöglicht den Kauf von 5.500 Aktien des Unternehmens. Der Ausübungspreis entspricht dem Schlusskurs der Stammaktien von Aligos am Tag der Zuteilung. Die Aktien werden über einen Zeitraum von vier Jahren freigegeben, wobei 25 % nach dem ersten Jahr und der Rest in gleichen monatlichen Raten unter der Bedingung der fortgesetzten Beschäftigung freigegeben wird. Der Zuschuss wurde im Rahmen des Anreizplans 2024 von Aligos gewährt, der ausschließlich für Eigenkapitalvergaben an Neueinstellungen verwendet wird, in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 5,500 shares of the Company’s stock (the “Inducement Grant”) to a newly hired employee on December 10, 2024 (the “Grant Date”), in connection with the commencement of employment.
The Inducement Grant was granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to this individual entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.
The Inducement Grant has an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for diseases with high unmet medical need such as chronic hepatitis B infection (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding the Aligos’s mission to improve patient outcomes by developing best-in-class molecules for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
FAQ
What are the vesting terms for Aligos Therapeutics' December 2024 inducement grant?
How many shares were included in Aligos Therapeutics' December 2024 inducement grant?
What is the exercise price for ALGS December 2024 inducement grant?
Under which plan was the ALGS December 2024 inducement grant issued?
